A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM
Recruiting · Phase 3 · NCT06397131
Conditions: Macular Telangiectasia Type 2
At a glance
- Research payments reported, 2025
- $328,531
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Neurotech Pharmaceuticals
- Tested
- M-CHFM (combination_product), CHFM (combination_product)
- Dates
- Started 2025-03-06; completion 2028-07-24
- Results posted
- Not yet
The overall purpose of this global, multicenter, two cohort, central image evaluator masked study is to characterize the clinical safety and efficacy of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM) for the treatment of MacTel and to evaluate whether its safety profile and efficacy are comparable to those of NT-501 manufactured using the Clinical Hollow Fiber Membrane (CHFM).
From ClinicalTrials.gov, last updated 2026-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Neurotech Pharmaceuticals, Inc. reported $328,531 in research payments for this study in 2025 (45 payments).
Products named: Encelto
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Roger A. Goldberg, MD Retina Specialist · Walnut Creek, CA
- Liliya S. Sutherland, D.O. Retina Specialist · Grand Rapids, MI
- Glenn Jaffe, M.D. Ophthalmology · Durham, NC
- Charles C. Wykoff, MD, PHD Ophthalmology · Bellaire, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Retina Consultants of Texas $132,657
- Foundation for Vision Research $116,370
- Duke University $44,873
- Bay Area Retina Associates $34,631
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.